Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials Prescription product net revenue of approximately $3.1 million in Q3 2022 increased 8.2% over Q2 2022 and increased approximately 412% over

Jaguar Health Provides Company Updates and Reports

2022 Third Quarter Financials

Prescription product net revenue of approximately

$3.1 million in Q3 2022 increased 8.2% over Q2 2022 and increased approximately 412% over prescription product net revenue in Q3 2021

Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) adding international sites,

targeting completion of enrollment in Q2 2023

of Phase 2 IIT study in peer reviewed journal Breast Cancer Research and Treatment

presentation in December 2022 from a third-party investigator, Dr. Mohamad Miqdady, Division Chief of the Pediatric Gastroenterology,

Hepatology & Nutrition Division at Sheikh Khalifa Medical City in Abu Dhabi, following initiation of proof-of-concept trial of

crofelemer for short bowel syndrome (SBS) and congenital diarrheal disorders (CCD), supporting the potential for expanded patient access

through programs in Europe in 2023

conditional approval for Canalevia , for exercise-induced diarrhea (EID), expected in Q1 2023, adding to ongoing commercial

activities of Canalevia-CA1 for treatment of chemotherapy-induced diarrhea (CID) in dogs

development activities with nondilutive funding for Jaguar's mental health Entheogen Therapeutics Initiative (ETI) program targeted

Canine Cancer: Take C.H.A.R.G.E. Registry honored by the MarCom Awards program with two Platinum awards and one Gold award

REMINDER: Jaguar to host investor

webcast Monday, November 14th at 8:30 a.m. Eastern regarding third quarter 2022 financials and company updates; Click here

to register for webcast

SAN FRANCISCO, CA / November 14, 2022 / Jaguar Health, Inc.

(NASDAQ: JAGX) ("Jaguar" or the "Company") today provided Company updates and reported consolidated third-quarter

2022 financial results.

The combined net revenue for Mytesi and the Company's

other prescription product, Canalevia -CA1, which became commercially available in April 2022, was approximately $3.1

million in the third quarter of 2022, representing an increase of 8.2% over prescription product net revenue in the second quarter of

2022, which totaled approximately $2.9 million, and an increase of approximately 412% over Mytesi net revenue in the third quarter of

2021, which totaled approximately $0.6 million.

"We are very pleased that growth in Mytesi (crofelemer) revenue

continued for the fifth quarter in a row in the third quarter of 2022," said Lisa Conte, Jaguar's president and CEO. "As previously

announced, the transition we completed throughout the end of 2021 and into the beginning of 2022 to a limited distribution network of

specialty pharmacies resulted in a meaningful reduction in Mytesi distribution costs as well as a higher average net price. It is wonderful

to see Mytesi growth continuing following this transition and the other components of our Mytesi patient access program, including our

ongoing educational and promotional activities in 2022 and the launch this past May of our telehealth initiative for Mytesi. Most

importantly, we are pleased with the realization of our mission of providing relief with a novel, plant-based, first-in-class mechanism

of action to patients in need - including patients for whom no alternative therapeutic options exist."

"As I frequently state, what is really powerful about crofelemer

is that it is a pipeline within a product, and we are focused on two late-stage clinical events in the next approximately 6 to 9 months

that we expect to be transformational in terms of value creation and recognition for the Company. Our key near-term clinical activity

is our Phase 3 pivotal OnTarget trial of crofelemer for our core follow-on indication of prophylaxis of cancer therapy-related

diarrhea (CTD). We expect enrollment in this pivotal trial to complete in the second quarter of 2023," Conte said. "Our second

prioritized clinical program centers around our approved investigator-initiated proof-of-concept trial of crofelemer for short bowel

syndrome (SBS) and congenital diarrheal disorders (CDD). SBS and CDD are devastating and often catastrophic diseases for patients, who

are frequently on parenteral nutrition for as long as 20 hours a day, seven days a week. The third-party investigator is targeting a

presentation following the initiation of this proof-of-concept study at next month's World Congress of Gastroenterology -

a global GI conference in Dubai. Additional investigator-initiated requests and trials and clinical data for SBS and CDD are expected

to come throughout 2023. In accordance with the guidelines of specific European Union countries, publications of proof-of concept data

from these trials could support early patient access to crofelemer for SBS or CDD with intestinal failure within 2023 through programs

in Europe. Early access programs are revenue generating, and reimbursable for participating patients."

2022 MILESTONES, UPDATES & ACCOMPLISHMENTS:

2022 THIRD QUARTER COMPANY FINANCIAL RESULTS:

Prescription product net revenue was approximately $3.1 million in

the third quarter of 2022, representing an increase of 8.2% over prescription product net revenue in the second quarter of 2022, which

totaled approximately $2.9 million, and an increase of approximately 412% over prescription product net revenue in the third quarter of

2021, which totaled approximately $0.6 million.

"Mytesi total prescription volume increased approximately 3%

in the third quarter of 2022 over the second quarter of 2022," said Ian Wendt, Jaguar's Chief Commercial Officer. "As previously

announced, the transition we completed this past January to a limited distribution network of specialty pharmacies resulted in a

meaningful reduction in Mytesi distribution costs as well as a higher average net price. I am very pleased to report that we significantly

outperformed the industry gross-to-net average in the third quarter of 2022 - as we did in the three previous quarters - for

sales of our human prescription product. This improvement in our gross-to-net was largely a result of the efficiencies realized by the

transition to a closed network of specialty pharmacies. This transition assists in the preparation of the Company's U.S. commercial

distribution network for potential future indication expansion of crofelemer to other populations of patients with complex medical needs,

such as CTD, inflammatory bowel disease, and SBS."

The Company believes the availability of Mytesi through specialty pharmacies

represents a significant benefit to patients, as such pharmacies focus on complex and chronic conditions and offer a higher level of support

for prior authorizations, appeals, adherence reminders, counseling, and home delivery options.

Note Regarding Use of Non-GAAP Measures

The Company supplements its condensed consolidated financial statements

presented on a GAAP basis by providing non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC

rules. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects

the basis upon which Company management assesses and operates the business. These non-GAAP financial measures are not in accordance with

GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior

to, measures of financial performance in conformity with GAAP.

The Company defines non-GAAP EBITDA as net loss before interest expense

and other expense, depreciation of property and equipment, amortization of intangible assets, share-based compensation expense and provision

for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring

revenues and expenses. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar's

performance and provide useful information to investors regarding the Company's results of operations and financial condition.

Participation Instructions for Webcast

When: Monday, November 14, 2022, at 8:30

Participant Registration & Access Link:

Replay Instructions for Webcast

Replay of the webcast on the investor relations

section of Jaguar's website: (click here)

About Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics &

Jaguar Animal Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company

focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress,

including chronic, debilitating diarrhea. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing

and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer

drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea

in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo

EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access

in Europe. Jaguar Animal Health is a tradename of Jaguar Health.

For more information about Jaguar Health, please visit https://jaguar.health.

For more information about Napo Pharmaceuticals, visit www.napopharma.com.

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic

relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment

of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered,